LGND — Ligand Pharmaceuticals Incorporated stock price and chart

Share this page

LGND

$295.54-0.99%

as of close, Oct 16, 2026

☾ AH $295.54 -0.99%

Ligand Pharmaceuticals IncorporatedStock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.01%Russell 3000 0.009%US Stock Market 0.008%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeSEEEE

20162019202120242026

50.0100.0150.0200.0250.0300.0010.0M20.0M$295.54

2026-10-16

Price$295.54

MA20$278.19

MA50$226.74

Vol1.3M

What would $1,000 invested in LGND be worth today? →

LGND returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $295.54
YTD price return: +56.31%
YTD total return: +56.31%
Next earnings: Nov 5, 2026
Market cap: 5.9B2016-12 1.3B2026-10 5.9B+345.0% over the window
Enterprise value: 5.7B
Shares outstanding: 19.9M2016-06 20.9M2026-06 19.9M-4.4% over the window
52W low: $175.89
52W high: $326.63
From 52W high: -9.52%
From 52W low: +68.03%
52W range: 79%

Volume

Rel volume: 0.65×
30D volume: 253.7K
30D $ vol: 75.2M

Fundamentals

Sales (ttm): 290.5M2016-06 88.1M2026-06 290.5M+229.9% over the window
Sales/share: $14.572016-06 $4.222026-06 $14.57+245.1% over the window
EPS (ttm): $9.502016-06 $9.572026-06 $9.50-0.7% over the window
FCF (ttm): 131.4M2016-06 46.5M2026-06 131.4M+182.7% over the window
FCF/share: $6.592016-06 $2.232026-06 $6.59+195.7% over the window
Book value/share: $48.532016-06 $15.812026-06 $48.53+206.9% over the window
Net margin: 67.88%2016-06 233.9%2026-06 67.9%-71.0% over the window
ROE: 20.38%2016-06 62.5%2026-06 20.4%-67.4% over the window
ROA: 9.02%2016-06 34.9%2026-06 9.0%-74.2% over the window
Debt / equity: 1.16×
Current ratio: 31.182016-06 0.572026-06 31.18+5328.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: +54.93%2025-06-30 → 2026-06-30187.6M → 290.5M (+54.9% total)+17.31%2023-06-30 → 2026-06-30179.9M → 290.5M (+61.5% total)+4.13%2021-06-30 → 2026-06-30237.3M → 290.5M (+22.4% total)+12.68%2016-06-30 → 2026-06-3088.1M → 290.5M (+229.9% total)
Net income: n/a+93.62%2023-06-30 → 2026-06-3027.2M → 197.2M (+626.2% total)+32.73%2021-06-30 → 2026-06-3047.9M → 197.2M (+311.8% total)-0.43%2016-06-30 → 2026-06-30205.9M → 197.2M (-4.2% total)
FCF: +145.28%2025-06-30 → 2026-06-3053.6M → 131.4M (+145.1% total)+10.00%2023-06-30 → 2026-06-3098.8M → 131.4M (+33.1% total)+29.60%2021-06-30 → 2026-06-3036M → 131.4M (+265.6% total)+10.95%2016-06-30 → 2026-06-3046.5M → 131.4M (+182.7% total)
Shares: +1.73%2025-06-30 → 2026-06-3019.6M → 19.9M (+1.7% total)+4.73%2023-06-30 → 2026-06-3017.4M → 19.9M (+14.9% total)+3.64%2021-06-30 → 2026-06-3016.7M → 19.9M (+19.5% total)-0.45%2016-06-30 → 2026-06-3020.9M → 19.9M (-4.4% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: n/a+81.98%2023-06-30 → 2026-06-30$1.58 → $9.50 (+502.9% total)+27.96%2021-06-30 → 2026-06-30$2.77 → $9.50 (+243.1% total)-0.07%2016-06-30 → 2026-06-30$9.57 → $9.50 (-0.7% total)
Sales/share: +52.30%2025-06-30 → 2026-06-30$9.57 → $14.57 (+52.3% total)+12.02%2023-06-30 → 2026-06-30$10.37 → $14.57 (+40.6% total)+0.48%2021-06-30 → 2026-06-30$14.23 → $14.57 (+2.4% total)+13.19%2016-06-30 → 2026-06-30$4.22 → $14.57 (+245.1% total)
FCF/share: +141.11%2025-06-30 → 2026-06-30$2.74 → $6.59 (+141.0% total)+5.03%2023-06-30 → 2026-06-30$5.69 → $6.59 (+15.9% total)+25.06%2021-06-30 → 2026-06-30$2.16 → $6.59 (+205.8% total)+11.45%2016-06-30 → 2026-06-30$2.23 → $6.59 (+195.7% total)
Book value/share: +14.97%2025-06-30 → 2026-06-30$42.22 → $48.53 (+15.0% total)+8.20%2023-06-30 → 2026-06-30$38.31 → $48.53 (+26.7% total)+0.57%2021-06-30 → 2026-06-30$47.16 → $48.53 (+2.9% total)+11.87%2016-06-30 → 2026-06-30$15.81 → $48.53 (+206.9% total)
Price: +63.54%2025-10-16 → 2026-10-16$180.77 → $295.54 (+63.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+73.65%2023-10-16 → 2026-10-16$56.42 → $295.54 (+423.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+29.45%2021-10-15 → 2026-10-16$81.26 → $295.54 (+263.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+17.66%2016-10-14 → 2026-10-16$58.10 → $295.54 (+408.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +63.54%2025-10-16 → 2026-10-16$180.77 → $295.54 (+63.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+73.65%2023-10-16 → 2026-10-16$56.42 → $295.54 (+423.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+29.45%2021-10-15 → 2026-10-16$81.26 → $295.54 (+263.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+17.66%2016-10-14 → 2026-10-16$58.10 → $295.54 (+408.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 31.1×2016-12 169.202026-10 29.89-82.3% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 62.2×2016-12 37.272026-10 62.23+67.0% over the window
Fwd P/E: 25.2×
P/S (ttm)Market cap ÷ TTM revenue.: 20.3×2016-12 14.402026-10 20.29+40.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 6.1×2016-12 3.922026-10 6.09+55.6% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 44.8×2016-12 24.612026-10 44.85+82.2% over the window
EV/EBITDA (fy): 44.4×
EV/Sales (ttm): 19.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.23%2016-09 4.1%2026-06 2.1%-48.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 19.9M ÷ 19.6M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -1.73%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-1.73%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($2.2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -1.73%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($75M) ÷ today's market cap ($5.9B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 1.27%2016-09 0.0%2026-06 1.2%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $75M + TTM dividends $0) ÷ today's market cap ($5.9B). Same caveat as the cash buyback yield.: 1.27%2016-09 0.0%2026-06 1.2%

Vs own 10Y history

P/E: 55th
P/OI: 73rd
P/S: 96th
P/B: 98th
P/FCF: 89th

Bar = where today’s multiple sits in LGND’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-0.99%

-2.08%

+7.39%

-0.31%

YTD

+56.31%

+63.49%

+263.70%

Financial statements

Open full LGND financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

LGND — Ligand Pharmaceuticals Incorporated price, chart and key statistics